Ʒһɫ

Retrospective

Gordon Shore (1945—2018)

John Bergeron Richard  Rachubinski
By John Bergeron and Richard Rachubinski
Jan. 1, 2019

Gordon Shore, a professor at McGill University, passed away Sept. 7 after a long and courageous battle with pancreatic cancer. We remember him as a wonderful husband and father, a steadfast friend and supporter of the community of biomedical scientists in Canada and abroad.

Gordon ShoreGordon ShoreGordon Shore, a professor at McGill University, passed away Sept. 7 after a long and courageous battle with pancreatic cancer. We remember him as a wonderful husband and father, a steadfast friend and supporter of the community of biomedical scientists in Canada and abroad.

Mitochondria were the center of Gordon’s scientific life. The coincidence of the endosymbiotic origin of mitochondria and the origin of eukaryotes has captivated life scientists. Today, understanding mitochondrial function and dysfunction is key to understanding overall eukaryotic cell function and the cellular basis of human disease. Gordon’s contributions to our knowledge of mitochondria began with his early studies that revealed the significance of the links between mitochondria and the endoplasmic reticulum, or ER, in mammalian cells and culminated in elucidating the roles of mitochondria in cell survival and cell death and the relevance of these processes to disease, especially cancer.

Gordon’s early work in mitochondria was done as a postdoctoral fellow with Jamshed Tata at the National Institute of Medical Research in Mill Hill, United Kingdom, now part of the Francis Crick Institute in London. In 1977, Shore and Tata uncovered . Today we understand in great depth the molecular details validating this hypothesis, extending to the acquisition of lipids for mitochondrial biogenesis, to calcium flux, to the mechanisms underpinning mitochondrial division and cell death.

After he was recruited to Montreal in 1977, Gordon carved out his niche in the mitochondrial world. In a field of giants like Günter Blobel, Gottfried Schatz and Walter Neupert, Gordon made seminal of the and in mammalian cells.

In the early 1990s, Gordon began a long friendship with the late Stanley Korsemeyer to focus on play in this process. With the virologist Philip Branton, Gordon used the well-defined adenovirus infection model of apoptosis to unravel the . The intricate dance of the ER and mitochondria to coordinate cell death and cell death suppression was defined through Gordon’s work on . Gordon together with his former graduate student , now a professor at McGill, described the contribution of dynamin-related protein 1 in the remodeling of mitochondrial cristae upon activation of BIK and showed this process is .

Gordon was an inspiring leader in on the ER-mitochondrial axis and autophagy to the clinic. In 1988, he cofounded with Philip Branton a biotech company, GeminX, that developed a first-in-class Bcl-2 inhibitor that targets this process. Gordon expanded his role in drug development as the chief scientific officer at Therillia, a Montreal pharmaceutical company that identifies candidate drugs for the treatment of cancer. Truly, Gordon had a profound impact on our understanding of the basic biology and clinical implications of mitochondria. He has left an indelible mark on his chosen field of research.

Gordon’s scientific contributions are valuable and long lasting, but when those of us who knew him think of him, we will most remember his qualities as a friend and colleague. He was a kind, supportive, optimistic friend who made our lives the better for knowing him. He will be sadly missed.

We thank Kate Beckingham of Rice University, Houston; Phil Branton, Heidi McBride and Dave Thomas of McGill University, Montreal; Jam Tata of the NIMR, London; and Walter Neupert, University of Munich, Martinsreid, for comments and remembrances.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
John Bergeron
John Bergeron

John Bergeron is the Robert Reford professor emeritus and a professor of medicine at McGill University in Montreal.

Richard  Rachubinski
Richard Rachubinski

Richard Rachubinski is a distinguished university professor in the department of cell biology at the University of Alberta in Edmonton.

Related articles

Daniel N. Hebert (1962–2024)
Ineke Braakman, Maurizio Molinari, Reid Gilmore & Lila Gierasch
Donald J. Graves (1933–2024)
Lee Graves & Paul Graves
Gary Felsenfeld (1929–2024)
Michael M. Gottesman, Christopher Wanjek & Martin Gellert
Daniel E. Atkinson (1921 – 2024)
Catherine Clarke & Steven Clarke
Fred Goldberg (1942–2023)
George N. DeMartino

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in People

People highlights or most popular articles

In memoriam: Ralph G. Yount
In Memoriam

In memoriam: Ralph G. Yount

July 28, 2025

He was a professor emeritus of chemistry and biochemistry at Washington State University and an ASBMB member for 58 years.

From dust to discovery
Profile

From dust to discovery

July 23, 2025

From makeshift classrooms in Uganda to postdoctoral research in Chicago, MOSAIC scholar Elizabeth Kaweesa builds a legacy in women’s health.

Fliesler wins scientific and ethical awards
Member News

Fliesler wins scientific and ethical awards

July 21, 2025

He is being honored by the University at Buffalo and the American Oil Chemists' Society for his scientific achievements and ethical integrity.

Hope for a cure hangs on research
Essay

Hope for a cure hangs on research

July 17, 2025

Amid drastic proposed cuts to biomedical research, rare disease families like Hailey Adkisson’s fight for survival and hope. Without funding, science can’t “catch up” to help the patients who need it most.

Before we’ve lost what we can’t rebuild: Hope for prion disease
Feature

Before we’ve lost what we can’t rebuild: Hope for prion disease

July 15, 2025

Sonia Vallabh and Eric Minikel, a husband-and-wife team racing to cure prion disease, helped develop ION717, an antisense oligonucleotide treatment now in clinical trials. Their mission is personal — and just getting started.

ASBMB members recognized as Allen investigators
Member News

ASBMB members recognized as Allen investigators

July 14, 2025

Ileana Cristea, Sarah Cohen, Itay Budin and Christopher Obara are among 14 researchers selected as Allen Distinguished Investigators by the Paul G. Allen Family Foundation.